9
Participants
Start Date
December 31, 2011
Primary Completion Date
March 31, 2016
Study Completion Date
September 30, 2016
Raltegravir
Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Ritonavir-boosted protease inhibitor
Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Providence Health Care- St. Paul's Hospital, Vancouver
University Health Network - Toronto General Hospital Division, Toronto
Montreal Chest Institute, Montreal
Merck Sharp & Dohme LLC
INDUSTRY
CIHR Canadian HIV Trials Network
NETWORK
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER